Literature DB >> 1345893

Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension.

Y Tada1, Y Tsuda, T Otsuka, K Nagasawa, H Kimura, T Kusaba, T Sakata.   

Abstract

A 72-year-old woman with 5-year history of essential hypertension developed peritoneal tuberculosis. The patient's hypertension, which had been well-controlled by long-acting nifedipine, deteriorated after the administration of rifampicin, an antitubercular agent. During use of nifedipine and rifampicin, both the peak plasma concentration and the area under the curve of nifedipine decreased markedly to about 40% of those without rifampicin. The findings suggest that rifampicin may increase the elimination of nifedipine, presumably by induction of its hepatic metabolism. Nisoldipine, another calcium antagonist, also failed to lower the patient's blood pressure, when given in combination with rifampicin. Taken together, these findings indicate that more caution should be urged when calcium antagonist is prescribed along with rifampicin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345893     DOI: 10.1097/00000441-199201000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  8 in total

1.  The interaction between rifampicin and lamotrigine: A case report.

Authors:  Jan Wimpelmann; Hans Høvik; Bettina Riedel; Lars Slørdal
Journal:  Br J Clin Pharmacol       Date:  2019-05-29       Impact factor: 4.335

Review 2.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Effect of rifampin on enantioselective disposition and anti-hypertensive effect of benidipine.

Authors:  Yu Eun Sunwoo; Phuong Thi Thu Nguyen; Chin May Chien; Ji Young Ryu; Jihong Shon; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2019-01-30       Impact factor: 4.335

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

7.  Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact.

Authors:  A Agrawal; S K Agarwal; T Kaleekal; Y K Gupta
Journal:  Indian J Nephrol       Date:  2016-09

Review 8.  Tuberculosis and pharmacological interactions: A narrative review.

Authors:  Niccolò Riccardi; Diana Canetti; Paola Rodari; Giorgio Besozzi; Laura Saderi; Marco Dettori; Luigi R Codecasa; Giovanni Sotgiu
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.